Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Conclusions: A dose of 2.3 mg of ixazomib was well-tolerated in combination with induction chemotherapy among older patients with ALL, and is being tested in the expansion phase of this trial. The remission rate in this older adult population appears favorable in both Ph-negative and Ph-positive patients.Table.DisclosuresAmrein: Takeda: Research Funding. Fathi: Agios: Honoraria, Research Funding; Astellas: Honoraria; Boston Biomedical: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Research Funding; Jazz: Honoraria; Seattle Genetics: Consultancy, Honoraria; Takeda: Consultancy, Honoraria.

Source: Blood - November 21, 2018 Category: Hematology Authors: Amrein, P. C., Ballen, K. K., Blonquist, T. M., Brunner, A. M., Hobbs, G. S., Hock, H., McAfee, S. L., Moran, J. A., Bergeron, M., Foster, J., Bertoli, C., McGregor, K., Macrae, M., Burke, M., Behnan, T. T., Som, T. T., Ramos, A. Y., Vartanian, M. K., Lom Tags: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster II Source Type: research